Publication:
Interleukin-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients

dc.contributor.buuauthorACET ÖZTÜRK, NİLÜFER AYLİN
dc.contributor.buuauthorURSAVAŞ, AHMET
dc.contributor.buuauthorGÖREK DİLEKTAŞLI, ASLI
dc.contributor.buuauthorDEMİRDÖĞEN, EZGİ
dc.contributor.buuauthorCOŞKUN, NECMİYE FUNDA
dc.contributor.buuauthorEDİGER, DANE
dc.contributor.buuauthorUZASLAN, AYŞE ESRA
dc.contributor.buuauthorYÖYEN ERMİŞ, DİĞDEM
dc.contributor.buuauthorKARACA, MERT
dc.contributor.buuauthorTERZİ, ORKUN ERAY
dc.contributor.buuauthorBAYRAM, MERVE
dc.contributor.buuauthorÖMER TOPÇU, DİLARA
dc.contributor.buuauthorYigitliler, Busra
dc.contributor.buuauthorYURTTAŞ, AHMET
dc.contributor.buuauthorMaharramov, Shahriyar
dc.contributor.buuauthorYAZICI, GAMZE
dc.contributor.buuauthorORAL, HALUK BARBAROS
dc.contributor.buuauthorKARADAĞ, MEHMET
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi.
dc.contributor.orcid0000-0002-6375-1472
dc.contributor.orcid0000-0001-7099-9647
dc.contributor.orcid0000-0002-7400-9089
dc.contributor.orcid0000-0003-3604-8826
dc.contributor.orcid0000-0002-2954-4293
dc.contributor.orcid0000-0001-5871-8769
dc.contributor.orcid0000-0003-0463-6818
dc.contributor.orcid0000-0002-9027-1132
dc.contributor.researcheridAAG-7406-2021
dc.contributor.researcheridAAD-1271-2019
dc.contributor.researcheridAAH-3888-2021
dc.contributor.researcheridK-7285-2012
dc.contributor.researcheridAAG-8744-2021
dc.contributor.researcheridAAI-3169-2021
dc.contributor.researcheridJPK-7012-2023
dc.contributor.researcheridAAE-9142-2019
dc.date.accessioned2024-06-25T13:05:52Z
dc.date.available2024-06-25T13:05:52Z
dc.date.issued2021-01-01
dc.description.abstractBackground/aim: COVID-19 patients have a wide spectrum of disease severity. Several biomarkers were evaluated as predictors for progression towards severe disease. IL-21 is a member of common gamma-chain cytokine family and creates some specific effects during programming and maintenance of antiviral immunity. We aimed to assess IL-21 as a biomarker for diagnosis and outcome prediction in patients hospitalized with COVID-19. Materials and methods: Patients with a preliminary diagnosis of COVID-19 and pneumonia other than COVID-19 admitted to a tertiary care hospital were included consecutively in this comparative study. Results: The study population consisted of 51 patients with COVID-19 and 11 patients with non-COVID-19 pneumonia. Serum IL-21 concentration was markedly higher, and serum CRP concentration was significantly lower in COVID-19 patients compared to nonCOVID-19 pneumonia patients. Within COVID-19 patients, 10 patients showed radiological and clinical progression. Patients with clinical worsening had lower lymphocyte count and haemoglobin. In addition to that, deteriorating patients had higher urea, LDH levels, and elevated concentration of both IL-6 and IL-21. The cut-off value of 106 ng/L for IL-21 has 80.0% sensitivity, %60.9 specificity for discriminating patients with clinical worsening. Multivariable analysis performed to define risk factors for disease progression identified IL-6 and IL-21 as independent predictors. Odds ratio for serum IL-6 concentrations >_ 3.2 pg/mL was 8.07 (95% CI: 1.3747.50, p = 0.04) and odds ratio for serum IL-21 concentrations >_ 106 ng/L was 6.24 (95% CI: 1.04 - 37.3, p = 0.02). Conclusion: We identified specific differences in serum IL-21 between COVID-19 and non-COVID-19 pneumonia patients. Serum IL-21 measurement has promising predictive value for disease progression in COVID-19 patients. High serum IL-6 and IL-21 levels obtained upon admission are independent risk factors for clinical worsening.
dc.description.sponsorshipAHAY (Akcier Hastalklar Aratrma ve Yardmlama Dernei-Lung Diseases Research and Help Society)
dc.identifier.doi10.3906/sag-2102-24
dc.identifier.endpage+
dc.identifier.issn1300-0144
dc.identifier.issue5
dc.identifier.startpage2274
dc.identifier.urihttps://doi.org/10.3906/sag-2102-24
dc.identifier.urihttps://hdl.handle.net/11452/42380
dc.identifier.volume51
dc.identifier.wos000711339600006
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.journalTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCommunity-acquired pneumonia
dc.subjectSerum il-21 levels
dc.subjectTherapy
dc.subjectIl-15
dc.subjectCovid-19
dc.subjectInterleukin 21
dc.subjectPrognosis
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectMedicine, general & internal
dc.subjectGeneral & internal medicine
dc.titleInterleukin-21: A potential biomarker for diagnosis and predicting prognosis in covid-19 patients
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication1fbb03ab-16d7-4784-86fd-239b055bc24f
relation.isAuthorOfPublication09f93f96-5325-45e7-bf28-4ad8e8c46d6d
relation.isAuthorOfPublicationa71bfd48-897b-4983-87e7-11edc5ed438a
relation.isAuthorOfPublication2445e2a7-e9d2-4c20-b3a7-84945617a6a0
relation.isAuthorOfPublication061153e8-bbd9-4c2a-97f6-dc51171a1143
relation.isAuthorOfPublicationea25ddfe-3514-411c-8862-e891b0cd651b
relation.isAuthorOfPublication80df98cb-7a8e-4a6c-86c1-65dfe8f4e962
relation.isAuthorOfPublication2af06def-4b00-4fe9-a19d-defb59369991
relation.isAuthorOfPublication52dddfd9-75c4-47a7-af7f-838817a9043e
relation.isAuthorOfPublicationeff47579-f032-4751-9288-d091906693f6
relation.isAuthorOfPublicationebbe2d25-e35e-4f78-886a-9d70c941e7ec
relation.isAuthorOfPublication741a6bcc-d000-4866-8e9d-48d8bd365555
relation.isAuthorOfPublication98961191-98af-4c36-b15f-8b9cec2ade41
relation.isAuthorOfPublicationaaa08d5d-15fa-4418-979e-08025b400fd0
relation.isAuthorOfPublicationbc853dab-a811-42b9-b03b-6d5fe067efe8
relation.isAuthorOfPublicationd7720460-3eae-413a-9ffc-16d206d8b896
relation.isAuthorOfPublication.latestForDiscovery1fbb03ab-16d7-4784-86fd-239b055bc24f

Files

Collections